{
  "abstract": "Background\n\nGliomas, particularly glioblastomas (GBM), are the most aggressive primary brain tumors with poor prognosis and limited therapeutic options. Resistance to temozolomide and high tumor invasiveness underscore the urgent need for novel therapeutic agents.Methods\n\nWe performed a large-scale screening of 1,460 small-molecule compounds using three human glioma cell lines (U251, LN229, and A172) to identify candidate anti-glioma agents. Four compounds with limited prior investigation in gliomas-SM1-71 (TAK1 inhibitor), HDACs/mTOR Inhibitor 1, BGT226 (PI3K/mTOR inhibitor), and ON013100 (mitotic inhibitor)-were selected for detailed in vitro and in vivo evaluation. In vitro assays included cell viability (CCK-8), cell cycle analysis, apoptosis, migration, and invasion assays. In vivo efficacy was assessed in a subcutaneous xenograft mouse model.Results\n\nSM1-71, HDACs/mTOR Inhibitor 1, BGT226, and ON013100 significantly inhibited glioma cell proliferation, induced G2-phase cell cycle arrest, and promoted apoptosis. All four compounds suppressed glioma cell migration and invasion in vitro. In the xenograft model, SM1-71 and ON013100 showed the most pronounced tumor growth inhibition (~ 75% reduction), whereas BGT226 and HDACs/mTOR Inhibitor 1 exhibited moderate effects. Ki-67 immunostaining confirmed decreased tumor cell proliferation. No significant body weight loss was observed, although isolated mortality indicated the need for further toxicity evaluation.Conclusions\n\nThis study identifies four promising anti-glioma compounds with potent in vitro and in vivo activity, particularly SM1-71 and ON013100. These findings support further preclinical investigation of these compounds, particularly with respect to pharmacokinetics, blood-brain barrier penetration, toxicity, and combination with standard therapies.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, 266000, China.",
    "Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, 266000, China. cjh19940317@163.com.",
    "Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, 266000, China. xujian@qdu.edu.cn."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yahui Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Mingchen Xie"
    },
    {
      "affs": [
        0
      ],
      "name": "Hao Han"
    },
    {
      "affs": [
        0
      ],
      "name": "Xun Xie"
    },
    {
      "affs": [
        1
      ],
      "name": "Jianhua Cheng"
    },
    {
      "affs": [
        2
      ],
      "name": "Jian Xu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4mq42rgq718dy.bib",
  "cited_by": 0,
  "doi": "10.1186/s12967-026-08771-1",
  "fulltext_url": "https://europepmc.org/articles/PMC13718155",
  "id": "4mq42rgq718dy",
  "issns": [
    "1479-5876"
  ],
  "landing_url": "https://europepmc.org/article/MED/42958268",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Research"
    ],
    [
      "openalex",
      "2716|Glioma Diagnosis and Treatment"
    ]
  ],
  "openalex": "W7172494303",
  "pdf_url": "https://europepmc.org/articles/PMC13718155?pdf=render",
  "pmcid": "PMC13718155",
  "pmid": "42958268",
  "published": "2026-08-05",
  "publisher": "BMC",
  "ris": "https://research.draconitic.com/paper/4mq42rgq718dy.ris",
  "sources": [
    {
      "first_seen": "2026-11-01T00:20:47Z",
      "native_id": "MED:42958268",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42958268"
    },
    {
      "first_seen": "2026-11-02T12:22:16Z",
      "native_id": "PMC13718155",
      "source": "pmc",
      "url": "https://doi.org/10.1186/s12967-026-08771-1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2716|Glioma Diagnosis and Treatment",
      "subfield": "human-genetics"
    }
  ],
  "title": "Large-scale compound screening reveals sensitivities to SM1-71, HDACs/mTOR Inhibitor 1, BGT226, and ON013100 in glioma.",
  "title_text": "Large-scale compound screening reveals sensitivities to SM1-71, HDACs/mTOR Inhibitor 1, BGT226, and ON013100 in glioma.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-02T12:22:16Z",
  "url": "https://research.draconitic.com/paper/4mq42rgq718dy",
  "venue": "Journal of translational medicine",
  "versions": []
}